Key considerations for shortening your CAR-T manufacturing process
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Autologous CAR-T cell therapy has demonstrated clinical efficacy in the treatment of B-cell malignancies, with particular promise in relapsed and/or refractory patients. Given the critical condition of these patients, shortening the vein-to-vein time is expected to improve therapeutic outcomes. At the same time, shortening the production time of a CAR-T cell product has the advantage of increasing production capacity and reducing manufacturing costs.
In this webinar, we will discuss how to establish a robust and automated 1 week manufacturing process for fresh CAR-T cell products. Several key process development considerations will be discussed and evaluated, including shelf life of a fresh drug product and in-process controls using standard methods such as flow cytometry .
A robust and flexible 1 week process has been established on the CliniMACS Prodigy® Platform, including the possibility to extend the process duration to achieve higher cell yields if required. The process enables the production of highly potent CAR-T cells, as demonstrated by in vitro and in vivo efficacy studies. The 1 week process generates sufficient numbers of viable, CAR-T cells for autologous treatment of patients, as demonstrated for several CAR constructs.
Don't miss this opportunity to learn about:
- Hurdles you may face in shortening your CAR-T cell manufacturing process
- Overcoming these challenges by using a platform for automated CAR-T cell manufacturing
- Tackling obstacles related to in-process monitoring and QC of CAR-T cells produced in an accelerated manufacturing process
SPEAKERS
